logo
HHS to build Medicare, Medicaid database on autism, other chronic illnesses

HHS to build Medicare, Medicaid database on autism, other chronic illnesses

CNN07-05-2025

See all topics
The US Department of Health and Human Services on Wednesday unveiled a pilot program for the National Institutes of Health to tap into Medicare and Medicaid data in its search for the root causes of autism
The database — which HHS said will draw from insurance claims, medical records, and data from wearable technology such as smartwatches — is one of the first steps in HHS Secretary Robert F. Kennedy Jr.'s bid to find the causes of autism 'by September.'
Yet early signals from health officials that they would build a database to track autism were met with swift rebuke from advocacy organizations and doctors.
NIH Director Dr. Jay Bhattacharya's initial description last month of a 'new autism registry' with 'broad coverage' of the U.S. population raised red flags and questions about privacy, the Autism Science Foundation said in a statement shortly after the news. The Autism Self Advocacy Network lambasted the project as an example of how this administration has 'completely frozen out autistic people.'
HHS nodded to those concerns in its announcement Wednesday. It said NIH and Centers for Medicare & Medicaid Services will start with a data use agreement focused on Medicare and Medicaid enrollees diagnosed with autism spectrum disorder, then establish a 'secure tech-enabled mechanism' that will share data with 'timely, privacy and security compliant data exchange.' The agencies will eventually build the pilot database out to share data on chronic illnesses and their economic burden, HHS said.
'Ever since the registry was first announced, there was an enormous sense of fear in the autism community, and they have concerns: Who's going to have access to data? How are those data going to be used?' Helen Tager-Flusberg, director of Boston University's Center for Autism Research and leader of the Coalition of Autism Scientists, told CNN.
There are also limitations to CMS data, Tager-Flusberg said. 'If you're talking about Medicare and Medicaid, that only focuses on certain portions of the population.'
Medicaid is a federal and state partnership covering low-income adults and children. Medicare is a federal program primarily for Americans 65 and older, although younger people with disabilities are also enrolled.
There are permissible uses of CMS data for medical research but very stringent privacy laws, Jeff Wurzburg, former HHS general counsel and a health care regulatory attorney at Norton Rose Fulbright, told CNN before Wednesday's announcement. 'One of the primary, overarching goals of CMS is protection of the beneficiary. So it's certainly legitimate and reasonable to raise questions about how this data will be collected and protected.'
Autism advocates and scientists have also questioned Kennedy's claim that health agencies would find the causes of autism by September, a timeline that Bhattacharya already appeared to walk back.
'Science happens at its own pace. We're accelerating and cutting the red tape that normally comes with putting together a scientific program like this,' he told reporters on April 22. 'We'll have, I hope, in September, something that in place where the scientists that want to want to compete for these awards will be able to do that.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Benefits And Drawbacks Of RFK Jr.'s New COVID Vaccine Recommendations
The Benefits And Drawbacks Of RFK Jr.'s New COVID Vaccine Recommendations

Forbes

time20 minutes ago

  • Forbes

The Benefits And Drawbacks Of RFK Jr.'s New COVID Vaccine Recommendations

SAVANNAH, GA - DECEMBER 15: A nurse shows off a vial of the Pfizer-BioNTech COVID-19 vaccine ... More outside of the Chatham County Health Department on December 15, 2020 in Savannah, Georgia. (Photo by) RFK Jr. and the HHS will no longer recommend annual COVID-19 vaccines for healthy pregnant women and young adults, according to a video announcement posted on X May 27 by Secretary of Health and Human Services Robert F. Kennedy Jr. A few days later, the CDC took a slightly different stance and stated that children between the ages of 6 months and 17 years may get the COVID-19 vaccine through shared decision-making between parents and healthcare providers. The CDC also updated the adult immunization schedule to say there is 'no guidance' on use for pregnancy. These decisions have sparked much debate among public health experts, policymakers and government officials. Here are the pros and cons of such a policy shift. As Kennedy cited in his video announcement, the U.S. seems to be aligning its vaccine policy with other countries such as the U.K. and Australia that have stopped recommending routine COVID-19 vaccines for young healthy adults. In addition, according to the new recommendations, the focus of vaccinations will largely be on high-risk populations, namely those who are 65 years of age and older as well as younger individuals with at least one medical condition that puts them at high risk for COVID-19. This could allow resources and attention to be redirected to the populations that need the vaccine most. The new recommendations also demand evidence in answering important questions the public deserves to know. For younger healthy American adults, getting approval for the vaccine will require placebo-controlled trials to show a benefit for that particular population. As an example, does a healthy 31-year-old male with no medical problems need to get a COVID-19 booster every single year, even after having received several COVID-19 boosters in the past? These are the types of questions that all Americans would like to and deserve to know with respect to COVID vaccinations. On the flip side, the new recommendations have many public health experts concerned. Pregnant healthy females could be barred from getting the COVID-19 vaccine, since the CDC has failed to provide guidance on the issue. Without a strong recommendation from the CDC, many pregnant patients could face real barriers from insurance companies to cover the vaccine, according to The New York Times. Pregnant women are at high risk for COVID infection and complications because pregnancy results in a weakened immune system. As Dr. Steven Fleischman, President of the American College of Obstetricians and Gynecologists states, 'The science has not changed. It is very clear that COVID infection during pregnancy can be catastrophic and lead to major disability.' The new recommendations could harm vulnerable populations. In addition to potential decreased vaccination rates and adverse outcomes for pregnant females, children could also suffer. When pregnant females get vaccinated against COVID-19 in the third trimester, they are able to pass along antibodies and protection to their infants, who have not developed mature immune systems. If pregnant females do not get vaccinated, infants will lack these antibodies and could then go on to develop severe complications from the virus should they get infected. Finally, the new recommendations could limit access to the vaccine to those that want it. Private insurance companies usually require FDA approval and CDC recommendations to cover the vaccine as part of health insurance. The current CDC recommendations simply state young children may get the vaccine with shared-decision making, not outright stating that they should get the vaccine. In addition, the CDC falls short in explicitly recommending the vaccine for pregnant females. This could prevent private insurance companies from fully covering the vaccine. Ultimately, this may mean some pregnant women and those that cannot afford the vaccine may not have access to it. The new recommendations for the COVID-19 vaccine for children and pregnant females was made without the customary use of independent advisors, and could have important implications for public health. While aligning with international practices, the move could significantly limit the amount of vaccines available for millions of Americans.

New research presents promising findings on colorectal cancer treatment and prevention
New research presents promising findings on colorectal cancer treatment and prevention

CNN

time22 minutes ago

  • CNN

New research presents promising findings on colorectal cancer treatment and prevention

Colorectal cancer is the second most common cause of cancer deaths in the United States, according to the American Cancer Society. This year, the organization estimates that more than 150,000 Americans will be diagnosed with it and nearly 53,000 will die from it. New studies presented at the annual meeting of the American Society of Clinical Oncology, or ASCO, in the last few days offer promising findings for both pharmaceutical and lifestyle interventions, including the impact of diet and exercise. Diagnoses of colorectal cancer have been decreasing overall for decades, the American Cancer Society says, thanks in large part to better screening. But case rates are rising among younger adults, and research estimates that colorectal cancer will become the leading cause of cancer death among adults ages 20 to 49 by 2030. Earlier research has suggested that regular exercise can improve survival rates for colorectal cancer patients, and a new study – published in the New England Journal of Medicine and presented at the ASCO conference on Sunday – confirmed those findings with robust clinical trial data. Between 2009 and 2024, researchers followed nearly 900 colon cancer patients who had completed chemotherapy – half of whom received an informational booklet that encouraged them to adopt a healthy lifestyle with good nutrition and exercise the other half of whom were also matched with a physical activity consultant for three years. They found that there was a 28% reduction in the risk of recurrence or new cancer for patients on the exercise program, with a five-year disease-free survival rate of 80% for the group with an exercise consultant compared with 74% for the group who just received the booklet. In other words, the exercise program was found to prevent 1 out of every 16 patients from developing recurrent or new cancer. 'That magnitude is comparable to – and in many cases exceeds – the magnitude of benefit offered by a lot of our very good standard cancer drugs,' said Dr. Christopher Booth, a professor of oncology with Queen's University and co-author of the new study. 'Exercise really should be considered an essential component of treatment of colon cancer.' Work is still being done to understand why exercise can help reduce the risk of cancer, but experts say that it may have something to do with the ways exercise helps reduce inflammation in the body. Another new study presented at the ASCO conference on Sunday found that anti-inflammatory diets also helped improve survival rates for people with stage 3 colon cancer. Patients who consumed more anti-inflammatory diets – including coffee, tea and vegetables such as leafy greens – and engaged in higher levels of physical activity had a 63% lower risk of death compared to patients who consumed the most inflammatory diets – including things like red meat, processed meat, refined grains and sugar-sweetened beverages – and engaged in lower levels of physical activity, the study found. 'Actively, as a field, we're learning about the role of the immune system in cancer development, and inflammation is an immune response,' said Dr. Sara Char, a clinical fellow in Hematology and Oncology at Dana-Farber Cancer Institute and lead author of the study, and the rise of colorectal cancer cases in younger people suggests it's a critical piece of the puzzle. 'When we look at the incidence of colon cancer in younger individuals … that really suggests to us that there is something in the environment – either in the foods we eat, our lifestyles, the chemicals that could be in our foods, all sorts of different things – that are outside of just genetics alone that could be driving these rates,' she said. 'So it is incredibly important for us, as a field, to be thinking about how our diet and lifestyle impacts not just our risk of developing this cancer, but then how people fare after it.' Both Booth and Char said that colorectal cancer patients are often seeking ways to proactively manage their risk. 'I think that's it's very empowering for patients,' Booth said. 'It's also achievable for patients. This is a commitment, but it's something that patients can achieve.' In his study, an 'exercise prescription' was developed based on each individual's starting point. Most people were able to reach their target increase if they went for a brisk walk for about an hour three or four days per week, Booth said. Lifestyle interventions like exercise and diet are also 'sustainable for health systems,' he said, but it's key that the system helps support patients in accessing the resources needed for behavioral interventions. Another new study showed promising results that might represent a new standard-of-care for certain patients with advanced colon cancer. On Friday, drugmaker Pfizer presented data on a colorectal cancer drug, Braftovi, used in combination with a standard chemotherapy and an antibody drug. During the trial, the drug combo was shown to double the length of time patients with an aggressive form of colorectal cancer lived with treatment: an average of 30 months compared with 15 months using currently available treatments. Braftovi targets a mutation in a specific protein that can lead to abnormal cell growth, and it's already approved by the US Food and Drug Administration to treat some forms of cancer. The study, which was funded by Pfizer, published Friday in the New England Journal of Medicine. 'It's a targeted cancer therapy that really depends on knowing what's driving patients' cancer,' Pfizer CEO Dr. Albert Bourla told CNN. These targeted therapies are one of the biggest advancements in cancer treatment over the past two decades, he said, and it's easy to diagnose whether cancer patients have the specific mutation that Braftovi can treat. The latest data on treatment for colorectal cancer a 'very, very important finding,' Bourla said, and the drugmaker plans to seek additional approval to add the new indication to the drug's label.

Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions
Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions

Associated Press

time29 minutes ago

  • Associated Press

Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 1, 2025-- To address the rising costs of cancer drugs, investigators from The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, explored the impact of engaging a remote clinical pharmacist in reducing the total cost of care (TCOC) within the Enhancing Oncology Model (EOM) from the Centers for Medicare and Medicaid Services (CMS). From July 1, 2023, to December 31, 2024, seven ClinReview pharmacists (CRPs) within five EOM-participating practices in The Network evaluated more than 5,600 patients for medication initiatives. During the same period, The Network had 12 practices in the EOM nationwide, accounting for approximately 50% of all providers participating in the program. A total of 1,271 interventions were identified, with 1,180 accepted. The sum of TCOC reduction amounted to $8,982,235. Six medication initiatives were implemented and the breakdown of each initiative and average TCOC reduction per intervention are shown in the table below and will be presented in a rapid oral presentation at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting: In addition to the six medication initiatives outlined above, the CRPs contributed an additional $1,201,326 in medication savings associated with drug selection. 'With the national cost of cancer care estimated to exceed $245 billion by 2030, this study provides a clear roadmap for oncology practices looking to reduce costs and improve patient outcomes,' said lead author Daniel Kendzierski, PharmD, senior clinical pharmacist, The Network. 'These findings underscore the critical role of pharmacist-driven medication interventions in driving the success of value-based care models in oncology.' Study Methodology Medication initiatives were clinically evaluated and adopted at an individual practice level and included moAB dose rounding, pembrolizumab dose banding, biosimilar TIC to preferred products, use of a preferred PD-1 agent in metastatic NSCLC, decreased upfront usage of long-acting GF in metastatic cancer, and preferred use of zoledronic acid over alternatives. CRPs remotely reviewed oncology treatment orders for cost-savings opportunities, updated eligible treatments per practice protocols, or reviewed with the treating oncologist. Interventions were submitted by the CRPs into a tracking system and marked as an EOM-related intervention. TCOC reduction was calculated using the difference between the CMS allowable for the original treatment ordered and the new order. Other Research at ASCO 2025 Physicians in The Network are affiliated with dozens of studies being presented at ASCO 2025. Their research highlights clinical and operational findings covering key topics such as the impact of AI on care delivery, access to oncology resources for minority patient populations, and patient experiences with novel therapies. 'As cancer care costs continue to escalate, community oncology practices need novel therapies and innovative solutions to deliver high-quality, affordable care,' said Leslie Busby, MD, Pharmacy & Therapeutics Committee chair and incoming chief medical officer, The Network. 'Research presented at this year's ASCO around digital transformation and patient care delivery in community settings highlights the direct impact practices in The Network have on the communities they serve. This research helps inform how we can continue driving value-based care forward and improving cancer care for all oncology patients.' The Network is supported by McKesson, which has an unmatched portfolio of oncology businesses and partners that provide research, insights, technologies, and services that are helping address barriers and improve cancer and specialty care. At ASCO, McKesson-supported businesses including The Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 170 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies, and early-phase studies. Click here for a full list of SCRI-affiliated studies and presentations and here for Ontada-affiliated abstracts. Expert Panel on Precision Medicine in Community Oncology during ASCO 2025 Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 4, 2025, at 12:10pm ET, titled, 'The Future is Now: Digital Transformation Unleashes Precision Medicine in Community Oncology.' Click here to register and join the panelists as they share their insights and perspectives on actionable steps and solutions for community oncology practices to seamlessly integrate precision medicine into their care offerings: ### About The US Oncology Network Every day, The US Oncology Network (The Network) helps more than 2,700 independent providers deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure, and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere. About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. View source version on CONTACT: Media Contact The US Oncology Network Claire Crye, Communications [email protected] Health on behalf of The US Oncology Network Christine Murphy, Media Relations [email protected] KEYWORD: TEXAS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL PRACTICE MANAGEMENT MANAGED CARE ONCOLOGY SOURCE: The US Oncology Network Copyright Business Wire 2025. PUB: 06/01/2025 08:00 AM/DISC: 06/01/2025 08:01 AM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store